Moving screening and prevention care more upstream can help make an impact by getting patients diagnosed with cancer earlier, said Susan Sabo-Wagner, MSN, RN, OCN, executive director of clinical strategy for Oncology Consultants of Houston, Texas.
Screening and prevention of cancer needs to be a collaborative effort between oncology practices and primary care providers, explained Susan Sabo-Wagner, MSN, RN, OCN, executive director of clinical strategy for Oncology Consultants of Houston, Texas.
Transcript
Is there a way for oncology practices to partner with primary care providers to put more focus on screening and prevention?
This is a big initiative that we want to work with in our HOPE Initiative, eventually. We're starting right at the door when the patient is diagnosed, coming into our practice. We know that we can only make so much of an impact when a patient is diagnosed with cancer, right? However they come to us, if it's stage IV, if it's stage III, if it's stage I; however they come. We know, obviously, it would be much better if we can prevent it from being a stage IV, stage III, and that comes from screening and education and wellness and behavioral health.
One of the things that we believe is that if we can get our model upstream into primary care, the best way we can do that is if we can provide it in some kind of payer model so that people are actually incentivized to be able to do things like screening and prevention care and get out there and provide health literacy. Get out into the neighborhoods… we can see it on a map, who is not getting out there to get screened. So, if we can provide it in some kind of model where it is an entire package of primary care with specialty involved, and everybody is making their impact and being incentivized for it; while it sounds like a nice thing to do, making sure everybody's getting screened and getting their chronic illnesses and cancers caught early, it also will have to show some kind of [return on investment], and it has to be good for business and we believe that it can be. We believe that that's what is part of a really true value-based model.
If everyone got on board, we know there's research already out there, there's tons of research that shows the earlier that you intervene in a person's life, the better the outcomes are. As a cancer care center, we know that our specialty is an incredibly expensive specialty, but we didn't start it that way. We’re doing the best we can in terms of treating it and trying to keep costs down. But, we think that—not that someone else should do it and only them—we think that as a group from beginning to the end, we can all have an impact there.
Infertility Coverage Boosts ART Use and Pregnancy Success: Richard A. Brook, MS, MBA
August 26th 2025In this episode, Richard A. Brook, MS, MBA, discusses his study showing that infertility treatment coverage increases assisted reproductive technology (ART) use and improves pregnancy outcomes.
Listen
Clinical Advances in EGFR-Mutated NSCLC: Insights From MARIPOSA and FLAURA2
September 7th 2025Treatment of EGFR-mutated non–small cell lung cancer (NSCLC) is shifting toward next-generation sequencing and combination regimens that improve survival but increase toxicity, requiring individualized care.
Read More
Evolving Roles of Antibody-Drug Conjugates in the Treatment of NSCLC
September 7th 2025Antibody-drug conjugates are rapidly reshaping the treatment landscape of non–small cell lung cancer (NSCLC), with advances in design, clinical efficacy, and regulatory approvals tempered by ongoing challenges in toxicity, resistance, and biomarker optimization.
Read More